Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[I-124]-CPD-1028 in Solid Tumours
NCT02134340Phase 1Completed
- Sponsor
- Centre for Probe Development and Commercialization
- Start
- Jun 2014
- Primary completion
- Jun 2016
- Modality
- Antibody Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of I-124-CPD-1028 in solid tumor, sponsored by Centre for Probe Development and Commercialization. Primary endpoints: Evaluate safety of [I-124]-CPD-1028 Injection at 30 days and Obtain preliminary biodistribution data for [I-124]-CPD-1028 at 18 days. Started Jun 2014; status: completed.
02
Drugs
I-124-CPD-1028
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02134340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134340.